0,52 €
Deine Einschätzung
Tempramed Technologies Ltd. Aktie
Was spricht für und gegen Tempramed Technologies Ltd. in den nächsten Jahren?
Pro
Kontra
News
TempraMed beruft den führenden Diabetesforscher Professor Dr. Lutz Heinemann in sein Advisory Board
Der renommierte Experte für Insulinpharmakologie, Diabetestechnologie und die Stabilität temperaturempfindlicher Medikamente verstärkt das wissenschaftliche Führungsteam von TempraMed.
TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board
A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability joins TempraMed to strengthen scientific leadership.
Vancouver, BC – December
TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients
Vancouver, BC – December 8, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and

